For the Inventor, By the Inventor

Enter assignee name

Heidelberg, Germany

Affimed Gmbh

USPTO Granted Patents = 11

CIPO Patents = 2

EPO Patents = 10

Trademarks = 5

Forward Citations = 42

Loading Chart...

Loading Chart...

21 inventors (with patents filed for the assignee):

Uwe Reusch (11 out of 19 patents)

Martin Treder (8 out of 8 patents)

Erich Rajkovic (7 out of 10 patents)

4. Kristina Ellwanger (6 out of 11 patents)

5. Ivica Fucek (6 out of 11 patents)

6. Thorsten Ross (5 out of 5 patents)

7. Stefan Knackmuss (5 out of 15 patents)

8. Michael Weichel (3 out of 7 patents)

9. Michael Tesar (3 out of 3 patents)

10. Fabrice Le Gall (3 out of 8 patents)

11. Sergey Kipriyanov (3 out of 5 patents)

12. Joachim Koch (2 out of 2 patents)

13. Karin Hoffmann (2 out of 4 patents)

14. Melvyn Little (2 out of 23 patents)

15. Michael Kluge (2 out of 2 patents)

11 patents: Sort by Forward Citations

1. 12264198 - Tandem diabody for CD16A-directed NK-cell engagement (2025-04-01),

2. 12076384 - Bispecific EGFR/CD16 antigen-binding protein (2024-09-03),

3. 11572415 - Multivalent FV antibodies (2023-02-07),

4. 11535672 - Combination of an anti-CD16A antibody with a cytokine (2022-12-27),

5. 11510972 - Bispecific EGFR/CD16 antigen-binding protein (2022-11-29),

6. 11180558 - Tandem diabody for CD16A-directed NK-cell engagement (2021-11-23),

7. 11167029 - Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy (2021-11-09),

8. 11001633 - NK cell engaging antibody fusion constructs (2021-05-11),

9. 9701750 - Anti-CD16 binding molecules (2017-07-11),

10. 9226962 - Human CD3-specific antibody with immunosuppressive properties (2016-01-05),

11. 9035026 - Anti-CD16 binding molecules (2015-05-19),

Affimed is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for patients with cancer. Using its proprietary Redirected Optimized Cell Killing (ROC-KIT) platform, Affimed engineers innate immune cells to kill tumor cells while sparing healthy cells. The company's lead product candidate, AFM13, is being evaluated in clinical trials for the treatment of blood cancers. Affimed is dedicated to advancing its pipeline of novel, first-in-class immunotherapies to improve outcomes for cancer patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

11 Patents

#39 in Heidelberg

#3,493 in Germany

#50,249 in the World

Heidelberg, Germany

Affimed Gmbh

Forward Citations = 42

21 inventors:

Uwe Reusch (11 out of 19 patents)

Martin Treder (8 out of 8 patents)

Erich Rajkovic (7 out of 10 patents)

4. Kristina Ellwanger (6 out of 11 patents)

5. Ivica Fucek (6 out of 11 patents)

Please report any incorrect information to support@idiyas.com

Loading…